Tessa Therapeutics Appoints CCO

Jennifer Butler has been appointed chief commercial officer, Tessa Therapeutics. In her new role, she will be responsible for driving the global launch and commercialization strategy of Tessa’s advanced T cell therapy pipeline, including the company’s lead product, TT10, which is currently in Phase III development for the treatment of nasopharyngeal carcinoma. Ms. Butler will be based in the U.S. and will be leading the expansion of the company's business operations there.

Ms. Butler has 20 years of pharmaceutical and biotechnology experience across several therapeutic areas, including global marketing, sales, and corporate strategy. Prior to joining the company, she spent 11 years in roles of increasing responsibility at AstraZeneca and MedImmune, the Biologics Division of AstraZeneca.  Ms. Butler most recently served as the head of global launch preparation and commercial strategy for AstraZeneca’s late-stage immuno-oncology programs, including recently launched Imfinzi / durvalumab (PD-L1).

"The addition of Jennifer to our global executive team will be instrumental as we prepare our organization for regulatory filings and commercial launches in the coming years," said Andrew Khoo, co-founder and chief executive officer of Tessa Therapeutics. "Her strong commercialization expertise and wealth of experience in bringing novel drugs and therapies to market will be invaluable to us as we progress our advanced immuno-oncology portfolio."